Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study-Reference-Cited by-同舟云学术

Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study

Published:2022-02-09 Issue:3 Volume:40 Page:650-659
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Wu Jing-Jing,Wang Wen-Hua,Dong Meng,Ma Shan-Shan,Zhang Xu-Dong,Zhu Li-Nan,Niu Song-Tao,Ding Meng-Jie,Zhang Jie-Ming,Zhang Lei,Li Xin,Li Ling,Sun Zhen-Chang,Wang Xin-Hua,Fu Xiao-Rui,Li Zhao-Ming,Chang Yu,Nan Fei-Fei,Yan Jia-Qin,Yu Hui,Wu Xiao-Long,Zhou Zhi-Yuan,Zhang Ming-Zhi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01219-5.pdf

Reference34 articles.

1. Correia CE, Schaff LR, Grommes C (2020) Central nervous system lymphoma: Approach to diagnosis and treatment. Cancer J 26:241–252. https://doi.org/10.1097/ppo.0000000000000449

2. Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N et al (2021) Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol 23:122–133. https://doi.org/10.1093/neuonc/noaa145

3. Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundström C, Amini RM, Hagberg H (2017) Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence is increasing. Acta Oncol 56:599–607. https://doi.org/10.1080/0284186x.2016.1270465

4. Santambrogio E, Nicolosi M, Vassallo F, Castellino A, Novo M, Chiappella A, Vitolo U (2019) Aggressive non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. Expert Rev Hematol 12:787–796

5. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY et al (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 7:1018–1029. https://doi.org/10.1158/2159-8290.cd-17-0613

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review;World Neurosurgery;2024-08

2. Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma;Frontiers in Cardiovascular Medicine;2024-07-26

3. A systematic review of primary central nervous system lymphoma;Holistic Integrative Oncology;2024-05-11

4. Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis;Cancers;2024-02-21

5. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway;Journal of Cancer Research and Clinical Oncology;2024-02-21